MMPJoe, can you outline Generex goals for uplisting to NASDAQ by January 2019, I believe this is a matter of some concern to shareholders, you, too, I would think. By failing to uplist, shareholder confidence will fail and a large financial payout would be due.

Once Generex was removed from NASDAQ there was steady decline culminating in a 1000:1 R/S and reasonable financing terms were out of reach. Please comment if you can.